BACKGROUND: Cerebral radiation necrosis is a serious complication of radiation treatment for brain tumors. Therapeutic options include corticosteroids, anticoagulation and hyperbaric oxygen with limited efficacy. Bevacizumab, an antibody against VEGF had been reported to reduce edema in patients with suspected radiation necrosis. We retrospectively reviewed 6 patients with biopsy proven cerebral radiation necrosis treated with bevacizumab between 2006 and 2008. RESULTS: Interval MRI follow-up demonstrated radiographic response in all patients with an average reduction of 79% for the post gadolinium studies and 49% for the FLAIR images. The initial partial radiographic response was noted for up to a mean follow-up time of 5.9 months (6 weeks to 18 months). CONCLUSION: Bevacizumab appears to produce radiographic response and clinical benefits in the treatment of patients with cerebral radionecrosis.
BACKGROUND:Cerebral radiation necrosis is a serious complication of radiation treatment for brain tumors. Therapeutic options include corticosteroids, anticoagulation and hyperbaric oxygen with limited efficacy. Bevacizumab, an antibody against VEGF had been reported to reduce edema in patients with suspected radiation necrosis. We retrospectively reviewed 6 patients with biopsy proven cerebral radiation necrosis treated with bevacizumab between 2006 and 2008. RESULTS: Interval MRI follow-up demonstrated radiographic response in all patients with an average reduction of 79% for the post gadolinium studies and 49% for the FLAIR images. The initial partial radiographic response was noted for up to a mean follow-up time of 5.9 months (6 weeks to 18 months). CONCLUSION:Bevacizumab appears to produce radiographic response and clinical benefits in the treatment of patients with cerebral radionecrosis.
Authors: Marc C Chamberlain; Michael J Glantz; Lisa Chalmers; Alixis Van Horn; Andrew E Sloan Journal: J Neurooncol Date: 2006-08-31 Impact factor: 4.130
Authors: Rajan Jain; Lisa Scarpace; Shehanaz Ellika; Lonni R Schultz; Jack P Rock; Mark L Rosenblum; Suresh C Patel; Ting-Yim Lee; Tom Mikkelsen Journal: Neurosurgery Date: 2007-10 Impact factor: 4.654
Authors: P J Chuba; P Aronin; K Bhambhani; M Eichenhorn; L Zamarano; P Cianci; M Muhlbauer; A T Porter; J Fontanesi Journal: Cancer Date: 1997-11-15 Impact factor: 6.860
Authors: Jeremy D Ruben; Michael Dally; Michael Bailey; Robin Smith; Catriona A McLean; Pasqual Fedele Journal: Int J Radiat Oncol Biol Phys Date: 2006-03-06 Impact factor: 7.038
Authors: Nanthiya Sujijantarat; Christopher S Hong; Kent A Owusu; Aladine A Elsamadicy; Joseph P Antonios; Andrew B Koo; Joachim M Baehring; Veronica L Chiang Journal: J Neurooncol Date: 2020-06-29 Impact factor: 4.130
Authors: Nathan A Dahl; Arthur K Liu; Nicholas K Foreman; Melissa Widener; Laura Z Fenton; Margaret E Macy Journal: Childs Nerv Syst Date: 2019-07-31 Impact factor: 1.475
Authors: F Cardoso; E Senkus; A Costa; E Papadopoulos; M Aapro; F André; N Harbeck; B Aguilar Lopez; C H Barrios; J Bergh; L Biganzoli; C B Boers-Doets; M J Cardoso; L A Carey; J Cortés; G Curigliano; V Diéras; N S El Saghir; A Eniu; L Fallowfield; P A Francis; K Gelmon; S R D Johnston; B Kaufman; S Koppikar; I E Krop; M Mayer; G Nakigudde; B V Offersen; S Ohno; O Pagani; S Paluch-Shimon; F Penault-Llorca; A Prat; H S Rugo; G W Sledge; D Spence; C Thomssen; D A Vorobiof; B Xu; L Norton; E P Winer Journal: Ann Oncol Date: 2018-08-01 Impact factor: 32.976
Authors: Chong Duan; Carlos J Perez-Torres; Liya Yuan; John A Engelbach; Scott C Beeman; Christina I Tsien; Keith M Rich; Robert E Schmidt; Joseph J H Ackerman; Joel R Garbow Journal: J Neurooncol Date: 2017-04-19 Impact factor: 4.130